ATE434442T1 - Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser- sehkraftkorrektur-chirurgie - Google Patents

Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser- sehkraftkorrektur-chirurgie

Info

Publication number
ATE434442T1
ATE434442T1 AT01983945T AT01983945T ATE434442T1 AT E434442 T1 ATE434442 T1 AT E434442T1 AT 01983945 T AT01983945 T AT 01983945T AT 01983945 T AT01983945 T AT 01983945T AT E434442 T1 ATE434442 T1 AT E434442T1
Authority
AT
Austria
Prior art keywords
upa
surgery
subepithelial
impact
plasminogen activators
Prior art date
Application number
AT01983945T
Other languages
English (en)
Inventor
David M Silver
Adrienne Csutak
Andras Berta
Jozsef Tozser
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE434442T1 publication Critical patent/ATE434442T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01983945T 2000-10-13 2001-10-12 Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser- sehkraftkorrektur-chirurgie ATE434442T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24026400P 2000-10-13 2000-10-13
PCT/US2001/031849 WO2002030444A2 (en) 2000-10-13 2001-10-12 Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery

Publications (1)

Publication Number Publication Date
ATE434442T1 true ATE434442T1 (de) 2009-07-15

Family

ID=22905837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01983945T ATE434442T1 (de) 2000-10-13 2001-10-12 Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser- sehkraftkorrektur-chirurgie

Country Status (10)

Country Link
US (1) US7179461B2 (de)
EP (1) EP1324767B1 (de)
JP (1) JP2004510825A (de)
AT (1) ATE434442T1 (de)
AU (2) AU2002215334B2 (de)
CA (1) CA2423595C (de)
DE (1) DE60139078D1 (de)
DK (1) DK1324767T3 (de)
ES (1) ES2325681T3 (de)
WO (1) WO2002030444A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5812199A (en) * 1998-09-08 2000-03-27 E.I. Du Pont De Nemours And Company Plant farnesyltransferases
US8158589B2 (en) 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
WO2007120457A2 (en) * 2006-04-13 2007-10-25 Euclid Systems Corporation Composition and method for stabilizing corneal tissue after refractive surgery
HUP0600891A2 (en) * 2006-11-30 2008-11-28 Inno Tears Kft Method and kit for measuring the status of the fibrinolytic system
US8202272B2 (en) * 2007-07-19 2012-06-19 Avedro, Inc. Eye therapy system
US8992516B2 (en) * 2007-07-19 2015-03-31 Avedro, Inc. Eye therapy system
EP2224949B1 (de) * 2007-11-30 2012-10-17 University of Debrecen Verwendung von Plasminogen-Aktivator-Inhibitoren vom Urokinase-Typ zur Behandlung von kornealen Erkrankungen
US8545487B2 (en) * 2007-12-05 2013-10-01 Avedro Inc. Eye therapy system
US8409189B2 (en) * 2008-01-23 2013-04-02 Avedro, Inc. System and method for reshaping an eye feature
US8469952B2 (en) * 2008-01-23 2013-06-25 Avedro, Inc. System and method for positioning an eye therapy device
US20090187173A1 (en) * 2008-01-23 2009-07-23 David Muller System and method for reshaping an eye feature
US8348935B2 (en) 2008-01-23 2013-01-08 Avedro, Inc. System and method for reshaping an eye feature
US20090275936A1 (en) * 2008-05-01 2009-11-05 David Muller System and method for applying therapy to an eye using energy conduction
JP2012502763A (ja) * 2008-09-19 2012-02-02 アヴェドロ・インコーポレーテッド 眼療法システム
WO2010039854A1 (en) * 2008-09-30 2010-04-08 Neal Marshall Eye therapy system
WO2010039979A1 (en) * 2008-10-01 2010-04-08 Avedro, Inc. Eye therapy system
US8882757B2 (en) * 2008-11-11 2014-11-11 Avedro, Inc. Eye therapy system
WO2010115121A1 (en) * 2009-04-02 2010-10-07 Avedro, Inc. Eye therapy system
WO2010115109A1 (en) * 2009-04-02 2010-10-07 Avedro, Inc. Eye therapy system
JP2012522602A (ja) * 2009-04-02 2012-09-27 アヴェドロ・インコーポレーテッド 眼治療システム
WO2011050164A1 (en) 2009-10-21 2011-04-28 Avedro, Inc. Eye therapy
WO2011053768A2 (en) * 2009-10-30 2011-05-05 Avedro, Inc. System and method for stabilizing corneal tissue after treatment
WO2011116306A2 (en) 2010-03-19 2011-09-22 Avedro, Inc. Systems and methods for applying and monitoring eye therapy
WO2012162529A1 (en) 2011-05-24 2012-11-29 Avedro, Inc. Systems and methods for reshaping an eye feature
WO2012167260A2 (en) 2011-06-02 2012-12-06 Avedro, Inc. Systems and methods for monitoring time based photo active agent delivery or photo active marker presence
EP2872081B2 (de) 2012-07-16 2025-07-16 Avedro, Inc. Systeme zur hornhautvernetzung mit gepulstem licht
WO2014205145A1 (en) 2013-06-18 2014-12-24 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
US9498114B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
EP2839828A1 (de) * 2013-08-23 2015-02-25 Nitto Denko Corporation Verbindungen und Formulierungen zur Behandlung von Wunden
EP3212140B1 (de) 2014-10-27 2021-12-01 Avedro, Inc. Systeme zur vernetzung von behandlungen trockener augen
US10114205B2 (en) 2014-11-13 2018-10-30 Avedro, Inc. Multipass virtually imaged phased array etalon
EP3827792A1 (de) 2015-04-24 2021-06-02 Avedro, Inc. Systeme und verfahren zur lichtaktivierung eines an einem auge applizierten lichtsensibilisators
EP4483884A3 (de) 2015-05-22 2025-03-05 Avedro Inc. Systeme zur überwachung der vernetzungsaktivität für hornhautbehandlungen
WO2017015471A1 (en) 2015-07-21 2017-01-26 Avedro, Inc. Systems and methods for treaments of an eye with a photosensitizer
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5467089A (en) * 1977-11-07 1979-05-30 Dainippon Pharmaceut Co Ltd Urokinase composition
DE19901594A1 (de) 1999-01-16 2000-08-10 Hannes Edgar Kompa Arzneimittel zur Behandlung und Prävention von postoperativen Wundheilungsstörungen der Kornea ("haze") nach photorefraktiver Laserkeratektomie
CA2370504A1 (en) * 1999-04-29 2000-11-09 Ista Pharmaceuticals, Inc. Biochemical methods that eliminate corneal scars, opacification and haze

Also Published As

Publication number Publication date
WO2002030444A2 (en) 2002-04-18
AU2002215334B2 (en) 2005-11-10
AU1533402A (en) 2002-04-22
ES2325681T3 (es) 2009-09-14
EP1324767A2 (de) 2003-07-09
DE60139078D1 (de) 2009-08-06
EP1324767B1 (de) 2009-06-24
WO2002030444A3 (en) 2003-03-20
DK1324767T3 (da) 2009-08-10
CA2423595C (en) 2013-01-08
US20040001821A1 (en) 2004-01-01
US7179461B2 (en) 2007-02-20
CA2423595A1 (en) 2002-04-18
JP2004510825A (ja) 2004-04-08

Similar Documents

Publication Publication Date Title
AU1533402A (en) Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
DE69526340D1 (de) Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
CA2507375A1 (en) Use of rimexolone in the treatment of dry eye
MA26901A1 (fr) Nouvelle composition pharmaceutique
FI972781A0 (fi) Menetelmät ja koostumukset allergisen nuhan ja muiden sairauksien hoitamiseksi käyttäen dekarboetokyloratadieeniä
WO2001030380A3 (en) Methods and compositions for treatment of keratoconus using protease inhibitors
EP0834320A4 (de) Wirkstoff-zusammensetzung, die albumin als aktiven bestandteil erhaelt
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
ATE349244T1 (de) Verwendung von pirenoxin zum schutz des kornealgewebes während photokeratektomie
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
AU687906B2 (en) Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
DE69432608D1 (de) Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
HK1045645A1 (zh) 消除角膜瘢痕、浑浊化和混浊的生化方法
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
UA66757C2 (en) Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
WO2001097752A3 (en) Compositions comprising urokinase for modulating muscle contractility and angiogenisis
AU624466B2 (en) New thrombolytic compositions
GB9412131D0 (en) Thrombolytic composition
FI97225C (fi) Menetelmä terapeuttisesti käyttökelpoisten (4-amino-2,6-dimetyylifenyylisulfonyyli)nitrometaanijohdannaisten valmistamiseksi
WO2002040030A8 (en) Combination therapy for lowering and controlling intraocular pressure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties